This study is looking at bone health in people with Cystic Fibrosis (CF). Researchers want to understand how osteoporosis (weak bones) develops in CF patients. The study involves a main part where up to 100 people, including CF patients and healthy volunteers, will have a single visit for bone scans (DEXA and micro CT) and blood tests. A smaller group of about 10 adult CF patients with bone disease from the main study may then receive a medication called Denosumab (Prolia) every six months for up to five years. The main goal is to see how bone density changes over time, measured by DEXA and micro CT scans. You may be able to join if you are between 18 and 64 years old and have a confirmed CF diagnosis. The study status is currently unclear.

Study design

This is an interventional study with up to 100 participants. It includes a main study and a sub-study where some participants will receive Denosumab.

What's involved

If you join the main study, you will have a single visit for a DEXA scan, micro CT scan, and blood collection. If you are in the sub-study, you will receive Denosumab every 6 months for up to 5 years and return annually for repeat scans, blood tests, and to report any side effects.

Compensation

Not stated in the trial record.

Follow-up

Participants in the sub-study will be followed for up to 5 years, with DEXA and micro CT results measured at single timepoints and for changes over this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.